Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 18/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 11/20 | 0.51 |
| ▸ | FLT3 | P36888 | 10/20 | 0.51 |
| ▸ | KIT | P10721 | 10/20 | 0.51 |
| ▸ | PDGFRA | P16234 | 10/20 | 0.51 |
| ▸ | WNT3A | P56704 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2841162 | 0.92 | CSF1R (0.52) | CSF1RPDGFRBFLT3KITPDGFRA | |
| SCHEMBL14024749 | 0.90 | CSF1R (0.46) | CSF1RPDGFRBFLT3KITPDGFRA | |
| SCHEMBL13322415 | 0.88 | CSF1R (0.48) | CSF1RPDGFRBFLT3KITPDGFRA | |
| SCHEMBL2847584 | 0.88 | CSF1R (0.53) | CSF1RPDGFRBFLT3KITPDGFRA | |
| SCHEMBL2676708 | 0.87 | CSF1R (0.60) | CSF1RPDGFRBFLT3KITPDGFRA | |
| SCHEMBL13322440 | 0.86 | CSF1R (0.55) | CSF1RPDGFRBFLT3KITPDGFRA | |
| SCHEMBL2843732 | 0.86 | CSF1R (0.55) | CSF1RPDGFRBFLT3KITPDGFRA | |
| SCHEMBL2841263 | 0.85 | CSF1R (0.56) | CSF1RPDGFRBFLT3KITPDGFRA | |
| SCHEMBL2676728 | 0.85 | CSF1R (0.51) | CSF1RPDGFRBFLT3KITPDGFRA | |
| SCHEMBL2848322 | 0.84 | CSF1R (0.51) | CSF1RPDGFRBFLT3KITPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2152700-B1 | CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE | NOVARTIS AG (CH) | 2013-12-11 | — | — | EP | claimed |
| US-8293769-B2 | CSF-1R inhibitors, compositions, and methods of use | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | claimed |
| US-20100130490-A1 | CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE | NOVARTIS AG (CH) | 2010-05-27 | — | — | US | claimed |
| EP-2152700-B1 | CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE | NOVARTIS AG (CH) | 2013-12-11 | — | — | EP | disclosed |
| US-8293769-B2 | CSF-1R inhibitors, compositions, and methods of use | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-8293769-B2 | CSF-1R inhibitors, compositions, and methods of use | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-8293769-B2 | CSF-1R inhibitors, compositions, and methods of use | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20100130490-A1 | CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE | NOVARTIS AG (CH) | 2010-05-27 | — | — | US | disclosed |
| US-20100130490-A1 | CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE | NOVARTIS AG (CH) | 2010-05-27 | — | — | US | disclosed |
| US-20100130490-A1 | CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE | NOVARTIS AG (CH) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130490-A1 | CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE | CSF1R, CSF3R, FLT3 | CSF1R 1/4885PDGFRB 119/4885FLT3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.